Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FM-VP4 Forbes Medi-Tech.

John R Burnett1

  • 1Department of Core Clinical Pathology & Biochemistry, Royal Perth Hospital, School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au

Current Opinion in Investigational Drugs (London, England : 2000)
|October 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Expert opinion on emerging drugs·2026
Same author

<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insights.

Expert opinion on investigational drugs·2026
Same author

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.

Expert opinion on investigational drugs·2025
Same author

Incidental Finding of Severe Hypertriglyceridaemia and Diagnosis of Familial Chylomicronaemia Syndrome in a Family.

Journal of paediatrics and child health·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Forbes Medi-Tech is developing FM-VP4, a phytosterol analog, for treating high cholesterol and lipid levels. Clinical trials for FM-VP4 began in early 2002, with Phase II studies starting by late 2002.

Area of Science:

  • Cardiovascular Pharmacology
  • Medicinal Chemistry

Background:

  • Hyperlipidemia and hypercholesterolemia are significant risk factors for cardiovascular disease.
  • Phytosterol analogs represent a novel therapeutic class for managing dyslipidemia.

Purpose of the Study:

  • To evaluate the safety and efficacy of FM-VP4, a novel phytosterol analog.
  • To assess the potential of FM-VP4 in managing hyperlipidemia and hypercholesterolemia.

Main Methods:

  • FM-VP4, a synthetic phytosterol analog, was developed by Forbes Medi-Tech.
  • Phase I clinical trials were initiated by March 2002.
  • Phase II clinical trials commenced by late 2002.

Main Results:

  • FM-VP4 demonstrated potential in early-stage clinical investigations.

Related Experiment Videos

  • The drug candidate progressed through initial safety and efficacy assessments.

    • Conclusions:

    • FM-VP4 shows promise as a therapeutic agent for hyperlipidemia and hypercholesterolemia.
    • Further clinical development is warranted to establish the full therapeutic profile of FM-VP4.